Two Randomized Trials of Linaclotide for Chronic Constipation

This article presented the results of two phase 3 clinical trials — multicenter, randomized, double-blind, and placebo-controlled — that evaluated the efficacy and safety of linaclotide in the treatment of chronic functional constipation. Together, the studies included over 1,270 adult patients meeting Rome criteria for chronic constipation.

Participants were randomized to receive linaclotide 145 mcg or 290 mcg once daily or placebo for 12 weeks. Both doses demonstrated significant superiority over placebo in primary endpoints:

• Increased frequency of complete spontaneous bowel movements (≥3 per week)
• Improved stool consistency by the Bristol scale
• Reduced straining during evacuation
• Improved overall satisfaction with bowel habits

Linaclotide acts as a guanylate cyclase C (GC-C) receptor agonist on the luminal surface of intestinal epithelium, increasing chloride and bicarbonate secretion into the lumen and accelerating intestinal transit. The peptide has predominantly local action, with minimal systemic absorption.

The most common adverse event was diarrhea, occurring in 14-16% of linaclotide patients versus 5% with placebo. The results of these trials supported FDA approval of linaclotide for chronic constipation, representing a mechanistically distinct new therapeutic option for this prevalent condition.